Service
Protein Expression Trial Service
KAICO delivers 100% success in recombinant protein expression using silkworm pupae—fast, scalable, and ideal for complex proteins.
- Development
- Biotech and Lifescience
Company (SME/startup) / 中小企業・スタートアップ
Fukuoka, JapanKAICO, a startup originating from Kyushu University, has established a robust platform for producing high-quality recombinant proteins for pharmaceutical, vaccine, and research applications using its proprietary Silkworm-Baculovirus Expression System.
Building on this technology, KAICO is actively engaged in the development of both injectable and oral vaccines for human and veterinary use, as well as feed additives designed to enhance immune function in livestock, particularly pigs.
KAICO is currently advancing the development of an injectable norovirus vaccine, with a Phase I clinical trial planned for fiscal year 2026.
Business Domain / 分野
Business Type / 業種
Disease Area / 疾患領域
Modalities / モダリティ
Technologies / 技術
Additional questions
Researched company/organisation type / マッチングご希望企業・機関のタイプ
Researched disease area / マッチングご希望の疾患領域
Researched Modality / マッチングご希望のモダリティ
Researched Technologies / マッチングご希望の技術
Service
Protein Expression Trial Service
KAICO delivers 100% success in recombinant protein expression using silkworm pupae—fast, scalable, and ideal for complex proteins.